Адрес для переписки:Ханферьян Роман Авакович ФГБУН «Федеральный исследовательский центр питания, биотехнологии и безопасности пищи» 109240, Россия, Москва, Устьинский проезд, 2/14. Тел.: 8 (495) 698-53-45. Е-mail: khanferyan@ion иммунология, 2016. Т. 18, № 5. С. 437-442. doi: 10.15789/1563-0625-2016-5-437-442 © Евстратова В.С. и соавт., 2016 Immunologiya, 2016, Vol. 18, no. 5, pp. 437-442. doi: 10.15789/1563-0625-2016
Federal Research Center of Nutrition and Biotechnology, Moscow, Russian FederationAbstract. The study presents results concerning effects of H 3 /H 4 histamine receptors antagonist (Ciproxifan) upon in vitro chemokine secretion by dendritic cells (DC) and peripheral blood mononuclear cells (PBMC). We have been shown that in vitro inhibition of type H 3 /H 4 histamine receptor affects in different ways production of major chemokines by PBMC and DC, including eotaxin, RANTES, MCP-1, MIP-1α, MIP-1β, GRO-α, and IL-8. E.g., RANTES and GRO-α secretion in DC cultures was reduced, respectively, by 20% and 40%. Meanwhile, MIP-1β secretion was virtually unchanged, whereas MCP-1 secretion exhibited a four-fold increase. In PBMC cultures, the H 3 /H 4 receptor antagonist induced a significant increase in eotaxin, RANTES, MIP-1α, MIP-1β, GRO-α, and IL-8 secretion (p < 0.05).